Reference health
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
74/74 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 74 checked references that resolve
resolves10.1016/j.ccell.2017.07.007
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
resolves10.1016/j.cell.2018.02.060
Comprehensive Characterization of Cancer Driver Genes and Mutations
resolves10.1038/nature11003
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
resolves10.1016/j.ccr.2011.04.002
c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
resolves10.1016/j.cels.2019.07.006
Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation
resolves10.1126/scisignal.2003573
Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells
resolves10.1158/0008-5472.CAN-15-0727
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
resolves10.1158/2159-8290.CD-11-0347
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
resolves10.1038/nbt.1511
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
resolves10.1016/j.ccr.2011.06.009
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
resolves10.1038/nature13561
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
resolves10.1038/onc.2014.328
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer
resolves10.1016/j.cell.2015.05.033
Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer
resolves10.18632/oncotarget.11939
DOT1L promotes angiogenesis through cooperative regulation of VEGFR2 with ETS-1
resolves10.1073/pnas.1314124110
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
resolves10.1016/j.ccr.2013.01.023
Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer
resolves10.1158/2159-8290.CD-18-0444
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
resolves10.1038/nature11005
Systematic identification of genomic markers of drug sensitivity in cancer cells
resolves10.1038/s41586-019-1186-3
Next-generation characterization of the Cancer Cell Line Encyclopedia
resolves10.1016/j.cell.2018.08.058
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
resolves10.1093/jnci/djr523
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
resolves10.1038/s41586-019-0987-8
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
resolves10.1158/2159-8290.CD-10-0044
C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
resolves10.1126/science.aad6204
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
resolves10.1016/j.ebiom.2018.09.034
Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
resolves10.1038/s41591-018-0023-9
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
resolves10.1038/s41467-018-06916-5
Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration
resolves10.1038/ng.3984
Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
resolves10.1016/j.ccell.2017.06.010
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
resolves10.1158/2159-8290.CD-12-0446
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in
<i>KRAS</i>
-Mutant Lung Cancer
resolves10.1126/scitranslmed.aaw7999
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
resolves10.1038/nrc2899
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
resolves10.1158/2159-8290.CD-15-1105
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
resolves10.1016/j.cell.2009.02.037
A Two-Step Model for Colon Adenoma Initiation and Progression Caused by APC Loss
resolves10.1038/onc.2009.30
Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis
resolves10.1016/j.cell.2018.04.008
Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing
resolves10.1158/2159-8290.CD-16-0263
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
resolves10.1158/2159-8290.CD-11-0240
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
resolves10.1038/s41568-019-0179-8
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
resolves10.1158/2159-8290.CD-14-1236
Co-occurring Genomic Alterations Define Major Subsets of
<i>KRAS</i>
-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
resolves10.3390/molecules23081930
Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3
resolves10.1016/j.cell.2017.01.013
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
resolves10.1093/bioinformatics/btq170
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
resolves10.1093/bioinformatics/btx415
The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics
resolves10.1016/j.cell.2020.05.043
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
resolves10.1093/nar/gks1111
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
The 1 reference without a DOI — listed, not checked
no DOI — not checkedExtracting biological insights from the Project Achilles genome-scale CRISPR Screens in Cancer cell lines
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.molcel.2021.07.021"><img src="https://citestamp.com/citestamped/10.1016/j.molcel.2021.07.021/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.molcel.2021.07.021)